In the study conducted by Liolios et al. [28], the prostate-specific membrane antigen (PSMA) and gastrin-releasing peptide receptor (GRPR) were considered as valuable biological targets for the molecular imaging and therapy of prostate (PCa) and breast (BCa) cancer. Here, FOLH1 is linked to cancer.